Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
26 studies found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Urogenital Neoplasms"
Show Display Options
Rank Status Study
1 Recruiting Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy
Conditions: Recurrent Prostate Carcinoma;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer
Interventions: Drug: Aspirin;   Other: Laboratory Biomarker Analysis;   Drug: Metformin Hydrochloride;   Other: Placebo
2 Recruiting Collecting and Storing Blood and Tumor Tissue Samples From Patients Undergoing Prostatectomy or Transurethral Resection of the Prostate
Condition: Prostate Cancer
Intervention:
3 Recruiting Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors
Conditions: Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Procedure: Arterial Spin Labeling Magnetic Resonance Imaging;   Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging;   Procedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging;   Procedure: Perfusion Magnetic Resonance Imaging
4 Recruiting Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer
Condition: Ovarian Epithelial Cancer
Intervention: Drug: SPL-108
5 Recruiting Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Conditions: Prostate Cancer;   Sexual Dysfunction and Infertility;   Sexuality
Interventions: Other: communication intervention;   Other: counseling intervention;   Other: nutrition intervention;   Other: questionnaire administration
6 Recruiting Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
Condition: Bladder Cancer
Interventions: Biological: TICE Bacillus Calmette-Guerin (BCG);   Biological: PANVAC
7 Recruiting Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners
Conditions: Malignant Female Reproductive System Neoplasm;   Malignant Hepatobiliary Neoplasm;   Partner;   Stage III Breast Cancer;   Stage III Cervical Cancer;   Stage III Colorectal Cancer;   Stage III Lung Cancer;   Stage III Prostate Cancer;   Stage III Skin Melanoma;   Stage III Uterine Corpus Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Colorectal Cancer;   Stage IIIA Lung Carcinoma;   Stage IIIA Skin Melanoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Cervical Cancer;   Stage IIIB Colorectal Cancer;   Stage IIIB Lung Carcinoma;   Stage IIIB Skin Melanoma;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colorectal Cancer;   Stage IIIC Skin Melanoma;   Stage IIIC Uterine Corpus Cancer;   Stage IV Breast Cancer;   Stage IV Cervical Cancer;   Stage IV Colorectal Cancer;   Stage IV Lung Cancer;   Stage IV Prostate Cancer;   Stage IV Skin Melanoma;   Stage IV Uterine Corpus Cancer;   Stage IVA Cervical Cancer;   Stage IVA Colorectal Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Cervical Cancer;   Stage IVB Colorectal Cancer;   Stage IVB Uterine Corpus Cancer
Interventions: Behavioral: Cognitive Behavior Therapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Other: Survey Administration
8 Not yet recruiting Enzalutamide Before Surgery in Treating Patients With Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Stage I Renal Cell Cancer
Interventions: Drug: Enzalutamide;   Other: Laboratory Biomarker Analysis;   Procedure: Nephrectomy
9 Not yet recruiting Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
Conditions: Stage II Prostate Adenocarcinoma;   Stage III Prostate Adenocarcinoma
Interventions: Drug: Abiraterone Acetate;   Drug: Androgen Receptor Antagonist ARN-509;   Biological: Gonadotropin-releasing Hormone Analog;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Procedure: Radical Prostatectomy
10 Recruiting A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
Condition: Prostate Cancer
Interventions: Biological: pTVG-AR;   Biological: gm-csf
11 Recruiting Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
Condition: Prostate Cancer
Interventions: Radiation: Proton Beam Therapy;   Radiation: Intensity Modulated Radiation Therapy
12 Recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Clear Cell Adenocarcinoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Mucinous Adenocarcinoma;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinofibroma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
13 Recruiting Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Tumor;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Other: Pharmacological Study
14 Recruiting Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Conditions: Micropapillary Serous Carcinoma;   Ovarian Serous Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Tamoxifen Citrate;   Drug: Topotecan Hydrochloride;   Drug: Trametinib
15 Recruiting Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Condition: Metastatic Castrate Resistant Prostate Cancer
Interventions: Biological: Dendritic Cells DCVAC;   Biological: Placebo;   Drug: Docetaxel;   Drug: Taxotere
16 Recruiting S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: TAK-700;   Drug: Bicalutamide
17 Recruiting Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Condition: Kidney Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: sunitinib malate
18 Recruiting Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
Conditions: Clear Cell Renal Cell Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Penile Carcinoma;   Renal Pelvis Urothelial Carcinoma;   Squamous Cell Carcinoma of the Penis;   Stage III Bladder Adenocarcinoma;   Stage III Bladder Squamous Cell Carcinoma;   Stage III Bladder Urothelial Carcinoma;   Stage III Penile Cancer;   Stage III Renal Cell Cancer;   Stage III Renal Pelvis Carcinoma;   Stage III Ureter Cancer;   Stage III Urethral Cancer;   Stage IIIa Penile Cancer;   Stage IIIb Penile Cancer;   Stage IV Bladder Adenocarcinoma;   Stage IV Bladder Squamous Cell Carcinoma;   Stage IV Bladder Urothelial Carcinoma;   Stage IV Penile Cancer;   Stage IV Renal Cell Cancer;   Stage IV Renal Pelvis Carcinoma;   Stage IV Ureter Cancer;   Stage IV Urethral Cancer;   Ureter Urothelial Carcinoma;   Urethral Urothelial Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
19 Recruiting A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Ovarian Neoplasms;   Peritoneal Neoplasms;   Fallopian Tube Neoplasms
Interventions: Drug: Trabectedin;   Drug: DOXIL;   Drug: Dexamethasone
20 Recruiting Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Conditions: Hematological Neoplasms;   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndromes;   Neoplasms;   Melanoma;   Breast Cancer;   Metastatic Breast Cancer;   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Glioblastoma Multiforme;   Osteosarcoma;   Sarcoma;   Thyroid Cancer;   Genitourinary
Interventions: Drug: CC-486;   Drug: Vidaza

   Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.